Clinical trials: Pancreatic Cancer Resectable
Neoplasms Pancreatic
PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer
PRIMUS 002 is looking at 2 different chemotherapy regimens in the neo-adjuvant setting for pancreatic cancer. Each treatment will be given for 3 months prior to surgery
- Trial name
- PRIMUS002 (NCT04176952)
- Testing
- FOLFOX-A, AG
- Where
- 3 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Judith Dixon-Hughes
Pancreatic Neoplasms
SBRT Pre-operatively for Pancreatic Cancer
In this study the investigators are testing if the addition of Stereotactic Body Radiation therapy (SBRT) prior to surgery improves surgical outcome in patients with borderline resectable or resectable pancreatic cancer (BRPC).
- Trial name
- SPARC (NCT02308722)
- Testing
- 5-fraction stereotactic body radiation therapy
- Where
- 5 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- University of Oxford
Cancer
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
RATIONALE: Antiemetic drugs may help to reduce or prevent vomiting in patients treated with radiation therapy. It is not yet known if ondansetron is more effective with or without dexamethasone in preventing vomiting caused by…
- Trial name
- NCT00016380
- Testing
- dexamethasone, ondansetron, quality-of-life assessment
- Where
- 14 sites in Canada
- Volunteers
- 211 people
- Sponsor
- NCIC Clinical Trials Group
Non-resectable Metastatic Cancer of the Lung, Non-resectable Metastatic Cancer of the Colon
Viewpoints on the Social Representations and Rationale Concerning the Choices of Patients, Doctors and Caregivers With Regard to the Management of Patients With Non-resectable Metastatic Cancer of the Colon, Stomach, Bile Ducts, Rectum, Pancreas or Lung, or Gastrointestinal Neuroendocrine Tumours
Reflexion on the therapeutic strategies to implement in patients at the end of life is advancing rapidly in France. However, beyond the choices presented to patients, sometimes even the decision to carry on, to limit or to stop…
- Conditions
- Non-resectable Metastatic Cancer of the Lung, Non-resectable Metastatic Cancer of the Colon, Non-resectable Metastatic Cancer of the Rectosigmoid Junction, Non-resectable Metastatic Cancer of the Stomach
- Trial name
- EOLE (NCT03328065)
- Testing
- Interviews, Questionnaires
- Where
- France
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Pancreatic Cancer
Gemcitabine With or Without Combination Chemotherapy and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, fluorouracil, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00416507
- Testing
- fluorouracil, gemcitabine hydrochloride, liposomal cisplatin
- Volunteers
- 190 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Pancreatic Cancer Resectable
Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer
Investigating the Optimal Duration of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer to Determine the True Surgical Indication.
- Trial name
- NCT06809374
- Testing
- gemcitabine
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Kochi University
Pancreatic Cancer, Neoadjuvant
An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer
An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer
- Trial name
- NCT06129812
- Testing
- Neoadjuvant treatment
- Volunteers
- 1,132 people
- Sponsor
- Seoul National University Hospital
Resectable Pancreatic Cancer
Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer
The goal of this clinical trial is to investigate if plasma ctDNA and eccDNA before resection for suspicion of pancreatic ductal adenocarcinoma (PDAC) can predict early recurrence and overall survival, and to investigate if…
- Trial name
- CIRCPAC (NCT05788744)
- Testing
- ctDNA
- Where
- 5 sites in Denmark
- Volunteers
- 1,000 people
- Sponsor
- Copenhagen University Hospital at Herlev
Pancreatic Adenocarcinoma Non-resectable
PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer
This is a single arm phase II trial assessing the potential activity of combination PEGPH20 plus Gemcitabine with radiotherapy in ten patients with localized, unresectable pancreatic adenocarcinoma.
- Trial name
- HALO-IST (NCT02910882)
- Testing
- PEGylated Recombinant Human Hyaluronidase (PEGPH20), Gemcitabine, Radiation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Scripps Health
Pancreatic Cancer Resectable
Early Diagnosis of Pancreatic Cancer Via Deciphering Multi-modal Immunological Signatures
Prospective inclusion of 1000 patients with pancreatic cancer (early-stage pancreatic cancer accounts for approximately 75% of cases), 1000 patients with benign pancreatic diseases, and 1000 healthy individuals as controls.
- Trial name
- NCT06495749
- Where
- 2 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Zhejiang University
Pancreatic Neoplasms, Biliary Tract Neoplasms
Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer
Randomized study comparing endoscopic stent insertion strategy versus double-bypass surgery in non-resectable periampullary cancer
- Conditions
- Pancreatic Neoplasms, Biliary Tract Neoplasms, Duodenal Neoplasms
- Trial name
- NCT00487851
- Testing
- surgery, endoscopic strategy
- Where
- Sweden
- Sponsor
- Karolinska Institutet
Pancreatic Cancer, Ampullary Cancer
Recurrence After Whipple's (RAW) Study
Pancreatic head malignancies are aggressive cancers that are often inoperable when they are diagnosed. In the ~20% of patients who are diagnosed when the disease is still operable, surgery is the only treatment that can provide a…
- Conditions
- Pancreatic Cancer, Ampullary Cancer, Bile Duct Cancer, Cholangiocarcinoma, Extrahepatic
- Trial name
- NCT04596865
- Testing
- Pancreaticoduodenectomy
- Where
- 29 sites in Australia, Austria and 6 more
- Volunteers
- 1,484 people
- Sponsor
- University Hospital Plymouth NHS Trust
Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy
The Impact of Hepatic Steatosis on Survival After Pancreaticoduodenectomy
We will use simple summaries, educational handouts, and discussions with doctors and nurses to explain this study. The study looks at patients with early-stage pancreatic cancer who undergo pancreaticoduodenectomy (Whipple…
- Trial name
- NCT07182136
- Testing
- Pancreaticoduodenectomy
- Volunteers
- 200 people
- Sponsor
- Wei-Hsun Lu